Literature DB >> 23636668

Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry.

Jong Wook Lee1, Jun Ho Jang, Jin Seok Kim, Sung-Soo Yoon, Je-Hwan Lee, Yeo-Kyeoung Kim, Deog-Yeon Jo, Jooseop Chung, Sang Kyun Sohn.   

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by chronic, complement-mediated hemolysis, frequently leading to debilitating clinical symptoms and life-threatening complications such as thromboembolism (TE). A retrospective analysis was performed on 301 patients from the South Korean National PNH Registry to describe disease burden and identify TE-associated risk factors. TE was identified in 18 % of patients and was associated with increased risk for mortality [odds ratio (OR), 6.85; P < 0.001]. A multivariate analysis showed that PNH patients with elevated hemolysis [lactate dehydrogenase (LDH) levels ≥1.5 times the upper limit of normal (ULN)] at diagnosis were at significantly higher risk for TE than patients with LDH <1.5 × ULN (OR 7.0; P = 0.013). The combination of LDH ≥1.5 × ULN with the clinical symptoms of abdominal pain, chest pain, dyspnea, or hemoglobinuria was associated with a greater increased risk for TE than elevated hemolysis or clinical symptoms alone. Continuous monitoring of these risk factors is critical for identifying PNH patients at risk for morbidities and mortality and allowing early intervention.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23636668     DOI: 10.1007/s12185-013-1346-4

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  31 in total

1.  Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology.

Authors:  G Socié; J Y Mary; A de Gramont; B Rio; M Leporrier; C Rose; P Heudier; H Rochant; J Y Cahn; E Gluckman
Journal:  Lancet       Date:  1996-08-31       Impact factor: 79.321

2.  Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria.

Authors:  Anita Hill; Russell P Rother; Xunde Wang; Sidney M Morris; Kerry Quinn-Senger; Richard Kelly; Stephen J Richards; Monica Bessler; Leonard Bell; Peter Hillmen; Mark T Gladwin
Journal:  Br J Haematol       Date:  2010-03-08       Impact factor: 6.998

3.  Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria.

Authors:  Anita Hill; Peter Hillmen; Stephen J Richards; Dupe Elebute; Judith C Marsh; Jason Chan; Christopher F Mojcik; Russell P Rother
Journal:  Blood       Date:  2005-06-28       Impact factor: 22.113

4.  Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria.

Authors:  T Wiedmer; S E Hall; T L Ortel; W H Kane; W F Rosse; P J Sims
Journal:  Blood       Date:  1993-08-15       Impact factor: 22.113

5.  Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan.

Authors:  Jun-Ichi Nishimura; Yuzuru Kanakura; Russell E Ware; Tsutomu Shichishima; Hideki Nakakuma; Haruhiko Ninomiya; Carlos M Decastro; Sharon Hall; Akihisa Kanamaru; Keith M Sullivan; Hideaki Mizoguchi; Mitsuhiro Omine; Taroh Kinoshita; Wendell F Rosse
Journal:  Medicine (Baltimore)       Date:  2004-05       Impact factor: 1.889

6.  Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays.

Authors:  Victor M Moyo; Galina L Mukhina; Elizabeth S Garrett; Robert A Brodsky
Journal:  Br J Haematol       Date:  2004-07       Impact factor: 6.998

7.  Intestinal infarction caused by paroxysmal nocturnal hemoglobinuria.

Authors:  M A Doukas; P E DiLorenzo; D N Mohler
Journal:  Am J Hematol       Date:  1984-01       Impact factor: 10.047

8.  Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories.

Authors:  Régis Peffault de Latour; Jean Yves Mary; Célia Salanoubat; Louis Terriou; Gabriel Etienne; Mohamad Mohty; Sophie Roth; Sophie de Guibert; Sebastien Maury; Jean Yves Cahn; Gerard Socié
Journal:  Blood       Date:  2008-06-05       Impact factor: 22.113

9.  Natural history of paroxysmal nocturnal hemoglobinuria.

Authors:  P Hillmen; S M Lewis; M Bessler; L Luzzatto; J V Dacie
Journal:  N Engl J Med       Date:  1995-11-09       Impact factor: 91.245

10.  Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.

Authors:  Robert A Brodsky; Neal S Young; Elisabetta Antonioli; Antonio M Risitano; Hubert Schrezenmeier; Jörg Schubert; Anna Gaya; Luke Coyle; Carlos de Castro; Chieh-Lin Fu; Jaroslaw P Maciejewski; Monica Bessler; Henk-André Kroon; Russell P Rother; Peter Hillmen
Journal:  Blood       Date:  2007-11-30       Impact factor: 22.113

View more
  34 in total

1.  Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study.

Authors:  Jong Wook Lee; Flore Sicre de Fontbrune; Lily Wong Lee Lee; Viviani Pessoa; Sandra Gualandro; Wolfgang Füreder; Vadim Ptushkin; Scott T Rottinghaus; Lori Volles; Lori Shafner; Rasha Aguzzi; Rajendra Pradhan; Hubert Schrezenmeier; Anita Hill
Journal:  Blood       Date:  2018-12-03       Impact factor: 22.113

2.  Clinical characteristics and therapeutic outcomes of paroxysmal nocturnal hemoglobinuria patients in Turkey: a multicenter experience.

Authors:  Deniz Goren Sahin; Olga Meltem Akay; Muzaffer Keklik; Vahap Okan; Abdullah Karakus; Cengiz Demir; Mehmet Ali Erkurt; Kadir Ilkkilic; Rahsan Yildirim; Gulsum Akgun Cagliyan; Salih Aksu; Mehmet Hilmi Dogu; Mehmet Sinan Dal; Volkan Karakus; Ali Ihsan Gemici; Hatice Terzi; Engin Kelkitli; Serdar Sivgin; Ali Unal; Mehmet Yilmaz; Orhan Ayyildiz; Serdal Korkmaz; Bulent Eser; Fevzi Altuntas
Journal:  Ann Hematol       Date:  2021-05-14       Impact factor: 3.673

3.  A comparative analysis of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria between Asia and Europe/America.

Authors:  Fan Yu; Yali Du; Bing Han
Journal:  Int J Hematol       Date:  2016-04-08       Impact factor: 2.490

4.  PNH is a debilitating, fatal but treatable disease: same disease, different clinical presentations.

Authors:  Fahri Sahin; Asu F Yilmaz; Melda Comert Ozkan; Nihal Mete Gokmen; Guray Saydam
Journal:  Am J Blood Res       Date:  2015-06-15

5.  Significant hemolysis is not required for thrombosis in paroxysmal nocturnal hemoglobinuria.

Authors:  Morag Griffin; Peter Hillmen; Talha Munir; Stephen Richards; Louise Arnold; Kathryn Riley; Anita Hill
Journal:  Haematologica       Date:  2018-10-04       Impact factor: 9.941

6.  Screening for paroxysmal nocturnal hemoglobinuria (PNH) in patients presenting with cerebral sinovenous thrombosis (CSVT): Results of a FLAER based flowcytometry study in Indian patients.

Authors:  Saniya Sharma; Jasmina Ahluwalia; Charu Batra Atreja; Manish Modi; Manupdesh Singh Sachdeva; Narender Kumar; Parveen Bose; Sunil Kumar Bose; Varun Uppal; Vivek Lal; Neelam Varma
Journal:  J Thromb Thrombolysis       Date:  2020-05       Impact factor: 2.300

7.  Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan.

Authors:  Haruhiko Ninomiya; Naoshi Obara; Shigeru Chiba; Kensuke Usuki; Kaichi Nishiwaki; Itaru Matsumura; Tsutomu Shichishima; Shinichiro Okamoto; Jun-Ichi Nishimura; Kazuma Ohyashiki; Shinji Nakao; Kiyoshi Ando; Yoshinobu Kanda; Tatsuya Kawaguchi; Hideki Nakakuma; Daisuke Harada; Hirozumi Akiyama; Taroh Kinoshita; Keiya Ozawa; Mitsuhiro Omine; Yuzuru Kanakura
Journal:  Int J Hematol       Date:  2016-07-27       Impact factor: 2.490

8.  Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry.

Authors:  Hubert Schrezenmeier; Petra Muus; Gérard Socié; Jeffrey Szer; Alvaro Urbano-Ispizua; Jaroslaw P Maciejewski; Robert A Brodsky; Monica Bessler; Yuzuru Kanakura; Wendell Rosse; Gus Khursigara; Camille Bedrosian; Peter Hillmen
Journal:  Haematologica       Date:  2014-01-31       Impact factor: 9.941

9.  Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies.

Authors:  Alexander Röth; Scott T Rottinghaus; Anita Hill; Eric S Bachman; Jin Seok Kim; Hubert Schrezenmeier; Louis Terriou; Álvaro Urbano-Ispizua; Richard A Wells; Jun Ho Jang; Austin G Kulasekararaj; Jeff Szer; Rasha Aguzzi; Andrew I Damokosh; Lori Shafner; Jong Wook Lee
Journal:  Blood Adv       Date:  2018-09-11

10.  Initial management of noncirrhotic splanchnic vein thrombosis: when is anticoagulation enough?

Authors:  Pranavi Ravichandran; Kris P Croome; Michael J Kovacs; Alejandro Lazo-Langner; Roberto Hernandez-Alejandro
Journal:  Can J Gastroenterol Hepatol       Date:  2014-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.